Chemical and Pharmaceutical Bulletin · 2011 · 15 citations · 2 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyEnzyme InhibitionLead Compound DesignLead DiscoveryNatural Product Drug DiscoveryReceptor PharmacologyStructure-activity Relationship AnalysisChemical Synthesis Of AnaloguesComparative Oral AbsorptionOral Absorption AssessmentPeroxisome Proliferator-activated Receptor Alpha (Ppar-alpha) SignalingPeroxisome Proliferator-activated Receptor Gamma AgonismPeroxisome Proliferator-activated Receptor SignalingPeroxisome Proliferator-activated ReceptorsProtein Tyrosine Phosphatase Inhibitors
2-Acyl-tetrahydroisoquinoline-3-carboxylic acid derivatives were synthesized and biologically evaluated. (S)-2-(2,4-Hexadienoyl)-7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (14) showed peroxisome proliferator-activated receptor γ (PPARγ) and PPARα agonist activities and protein-tyrosine phosphatase 1B (PTP-1B) inhibitory activities. PPARγ agonist activity of 14 was comparable to that of rosiglitazone, and PTP-1B inhibitory activity was about 10-fold weaker than that of ertiprotafib, a PTP-1B inhibitor. Compound 14 showed high oral absorption in rats and potent hypoglycemic effects in KK-A(y) mice. In conclusion, 14 would be an excellent lead compound for a new type of anti-diabetic drug with triple actions.
2
Satoru Azukizawa, Masayasu Kasai, Kenji Takahashi et al. · Chemical and Pharmaceutical Bulletin · 2008 · 30 citations · Full text